


Pediatric Neurology – A Color Handbook

This new book is written by specialist authors who recognise the needs of nonspecialists and trainees.

Recognising patterns of disease can be the first step to successful management of the child with a neurological problem; this is emphasised by the authors throughout the book. Their concise, precise account reflects the remarkable recent advances in paediatric neurology and related disciplines, while stressing the fundamentals of clinical examination and history taking in reaching an accurate diagnosis. The book

begins with a detailed discussion of neurological examination techniques and the basic formulation of differential diagnoses and management, using neuroradiology, electrophysiology, cerebrospinal fluids, genetic and metabolic testing. The second section of the book follows a problem-based



approach, just as diseases present in the real world. It employs practical, symptom- and sign-based strategies for virtually all conditions encountered by the practitioner. The final section on neurological emergencies recognises that such conditions present first to someone other than a paediatric neurologist.


Authors: James F Bale, Joshua L Bonkowski, Francis M Filloux, Gary L Hedlund, Denise M Nielsen, University of Utah School of Medicine, Salt Lake City, Utah, USA, Paul D Larsen, University of

Nebraska College of Medicine, USA.
ISBN 9781840761344.

For more information
Email. matt@mansonpublishing.com

Increase in sales of Ambu's Inoject needle

Ambu are a Danish headquartered company with an impressive portfolio of products. One product that is now making its way into many hospital departments and has seen a recent increase in demand is the Inoject needle used for EMG procedures. When asked why use of this needle seemed to be more frequent Chris Smith, UK sales manager for the range, replied "The Inoject needle provides superior performance with reduced friction for ease of skin penetration and a high quality signal for consistent reliable results, helping in the accurate use of Botulinum for many conditions. Inoject needles are currently being used for the relaxation of muscles that are spasmodic in the face, particularly around the eyes, head and neck. The needles also help bring relief to sufferers of cerebral palsy and other genetic nerve diseases, as well as general nerve spasms that cannot be relaxed by manipulation, including laryngeal spasms. These high quality products are available in a full range of sizes and I believe this is reflected in their popularity."



For more information Email. skg@ambu.com

Merck Serono submits application for extension of indication for Rebif® in Europe

Merck Serono, a division of Merck KGaA, Darmstadt, Germany has submitted an application to the European Medicines Agency (EMA) to extend the indication of Rebif®, its leading treatment for multiple sclerosis (MS). The requested label extension is for the use of Rebif® in patients who have experienced a single demyelinating event, an early sign of the disease, and who are at high risk of converting to MS.

"Our application to extend the indication of Rebif® is based on the REFLEX study, which focused on patients with early signs of multiple sclerosis," said Dr. Bernhard Kirschbaum, Executive Vice President for Global Research and Development at Merck Serono. "We remain strongly committed to addressing the medical needs of patients with multiple sclerosis at the various stages of this devastating disease."

Merck Serono's submission of a type II variation to extend the indication of Rebif® is supported by results of the REFLEX study, which were presented at the American Academy of Neurology (AAN) in April 2011. The REFLEX study was designed to evaluate the effect of two different doses of Rebif – the currently approved 44mcg three times a week and 44mcg once a week – versus placebo, on the "Time to conversion to McDonald MS (2005)" in patients with a first clinical demyelinating event and having magnetic resonance imaging (MRI) brain scans consistent with early signs of MS. The study met its primary endpoint for both doses by demonstrating that Rebif® significantly delayed conversion to McDonald MS (2005) in those patients.

The REFLEX study was conducted with the human serum albumin (HSA) – free formulation of Rebif®, which is now available in all European Union countries, Australia, Canada and Switzerland, as well as a number of countries in Asia, Latin America, Africa and the Middle East. The HSA-free formulation of Rebif® is currently not available in the United States.

Tremendous achievement of climbers with MS or PD

In July, 7 men and women with Multiple Sclerosis (MS) and 4 with Parkinson's disease (PD), along with nine climbing companions, reached the highest peak in Africa. This is the first time that a group of people with both of these neurodegenerative diseases have united to reach a summit this high. The climb clearly demonstrated that neurodegenerative diseases do not represent the end of

'normal' life. Mount Kilimanjaro in Tanzania stands at 19,340 feet, not only making it the highest peak in Africa, but also the highest free-standing mountain in the world.

"This 'Kilimanjaro Leap of Faith Adventure' was meant to challenge the body, expand the mind and foster courage in dealing with the diagnosis of a neurodegenerative disease. There have been some really tough parts of the trek, especially altitude sickness, for which there is nothing you can do. Imagine that on top of our neurodegenerative diseases. But, we've made it



and that's a credit to all of us who believe that we can go beyond the limitations of our disease and still achieve incredible results, both physically and mentally," said trip organiser Lori Schneider, founder of Empowerment Through Adventure.

"Most of the group dedicated themselves to training to prepare themselves for this challenge. A key attribute of the group is their

outstandingly positive outlook, regardless of the hurdles they face, and their unwavering commitment to supporting one another throughout the trip."

Communication activities for the Kilimanjaro Leap of Faith Adventure 2011 are kindly supported by Sanofi.

For further information on Empowerment Through Adventure see www.EmpowermentThroughAdventure.com